NYSE : PEN

Penumbra, Inc. — News

$323.02 USD

$1.83 (0.57%)

Volume
247.91K
Average Volume
413.17K
Market Capitalization
$12.72B
P/E Ratio
78.98
Dividend Yield
0.00%
Price Target
$347.00
Year High
$362.41
Year Low
$221.26
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$5.75
Source Headline
Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

prnewswire.com - 2026-07-30 16:05:00

Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN

Bank of Nova Scotia boosted its stake in Penumbra, Inc. (NYSE: PEN) by 14,837.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,820 shares of the company's stock after purchasing an additional 210,402 shares during the quarter. Bank

defenseworld.net - 2026-07-25 04:05:38

California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN

California Public Employees Retirement System lifted its stake in shares of Penumbra, Inc. (NYSE: PEN) by 25.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,421 shares of the company's stock after purchasing an additional 12,108 shares during

defenseworld.net - 2026-07-23 03:41:46

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal

gurufocus.com - 2026-07-22 15:00:00

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO).

prnewswire.com - 2026-07-22 14:35:00

Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in shares of Penumbra, Inc. (NYSE: PEN) by 0.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,527 shares of the company's stock after selling 2,129 shares during the

defenseworld.net - 2026-07-22 03:40:40

3 Medical Device Stocks Giving Investors a Different Healthcare Play

When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook.

marketbeat.com - 2026-07-20 09:40:05

IQV vs. PEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

zacks.com - 2026-07-14 12:40:26

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.

prnewswire.com - 2026-07-07 09:00:00

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com - 2026-06-22 12:41:09

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.

zacks.com - 2026-06-18 13:51:01

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally.

prnewswire.com - 2026-06-15 09:00:00

Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke.

prnewswire.com - 2026-06-11 16:05:00

GMED or PEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-06-05 12:40:28

Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:36:21

Artisan Small Cap Fund Q1 2026 Portfolio Activity

During the quarter, we initiated new Garden positions in Onto Innovation, Baldwin Group and Freshpet. In addition to Compass, we added to our positions in Ollie's Bargain Outlet and Flowserve during the quarter. We ended our investment campaigns in Penumbra, JBT Marel and Parsons during the quarter.

seekingalpha.com - 2026-05-07 09:15:00

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.

zacks.com - 2026-05-06 18:25:34

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

prnewswire.com - 2026-05-06 16:05:00

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com - 2026-05-05 12:41:09

Get PEN Insider Trade Alerts

PEN Price Target Summary

Last Month

$320.00

1 analysts

Last Quarter

$327.50

2 analysts

Last Year

$351.83

24 analysts

All Time

$299.33

54 analysts

PEN Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-06 Evercore ISI Group Maintain Outperform Outperform
2026-06-11 RBC Capital Maintain Sector Perform Sector Perform
2026-05-07 Citigroup Maintain Neutral Neutral
2026-05-07 Evercore ISI Group Maintain Outperform Outperform
2026-02-26 Evercore ISI Group Maintain Outperform Outperform
2026-01-20 Canaccord Genuity Downgrade Buy Hold
2026-01-20 RBC Capital Downgrade Outperform Sector Perform
2026-01-16 Leerink Partners Downgrade Outperform Market Perform
2026-01-16 Truist Securities Downgrade Buy Hold
2026-01-16 Citigroup Downgrade Buy Neutral
2026-01-16 Needham Downgrade Buy Hold
2026-01-16 Baird Downgrade Outperform Neutral
2026-01-16 BTIG Downgrade Buy Neutral
2026-01-16 Jefferies Downgrade Buy Hold
2026-01-15 William Blair Downgrade Outperform Market Perform
2026-01-15 Wells Fargo Downgrade Overweight Equal Weight
2026-01-05 B of A Securities Maintain Buy Buy